Table 1.
Baseline Patient Characteristics
| Patient | Age (years) | Stage | PSA (ng/ml) | Prostate Volume (grams) | Gleason Score | Risk Group^ | Interval gene transfer to RP (weeks) |
|---|---|---|---|---|---|---|---|
| A1 | 46 | pT2a | 5.8 | 22 | 5(3+2) | Low | 7.4 |
| A2 | 59 | pT3a | 15.6 | 14.5 | 7(3+4) | High | 10.4 |
| A3 | 66 | pT3a | 2.81 | 21 | 7(3+4) | High | 15.7 |
| A4 | 50 | pT2a | 8.85 | 80 | 5(2+3) | Low | 14.7 |
| A5* | 62 | ------- | 22.7 | ------- | n/a | High | ------- |
| A6 | 65 | pT3b | 11.8 | 48 | 8(4+4) | High | 9.4 |
| A7 | 54 | pT3a | 9.6 | 23 | 7(4+3) | High | 8.1 |
| A8 | 53 | pT2c | 4.53 | 12.5 | 7(3+4) | Intermediate | 8.3 |
| A9 | 61 | pT3a | 9 | 20 | 7(3+4) | High | 8.3 |
| A10 | 49 | pT3a | 3.4 | 23 | 7(3+4) | High | 7.3 |
*
Dropped out of study due to declining surgery
^
Based on National Comprehensive Cancer Network (NCCN) Guidelines